SYK — Stryker Corporation

Analyst positioning is broadly positive - 38 Buy ratings, 14 Holds, zero Sells, consensus target ~$381.59 - and the 9.4% Q2 2026 revenue rebound plus 68.3% gross margin validated the post-cyber recovery. But the stock's price action has not followed: RSI is 42.81, price is below the 20/50/200-day SMAs, and recent insider selling plus a high GAAP P/E keep sentiment from turning outright bullish.

Underlying growth is steady high-single-digit to low-double-digit, with Q1 2026 the clear exception: revenue rose 9.4% YoY in Q2 2026 to $6.589B after only +2.6% in Q1 2026 (the cyber-incident quarter), versus +11.4% in Q4 2025 and +10.2% in Q3 2025. Operating margin expanded to 25.2% in Q2 2026 from 22.6% a year earlier, and TTM free cash flow is about $4.7B. This is a one-quarter operational blip followed by a margin-accretive recovery, not a structural demand slowdown.

At $322.12, valuation is context-dependent: trailing GAAP P/E is 33.1x, P/S 4.78x, and P/B 5.15x, so it is not cheap on reported earnings. But on consensus forward EPS of $15.02, the forward P/E is roughly 21.4x, below the 5-year average P/S of 5.57 and consistent with a PEG of ~1.2. Relative to its own history, the stock is on the cheap side; in absolute terms, it remains a premium-quality medtech multiple.

At ~21x forward earnings, the market is pricing in a normal, not heroic, H2 2026: no multiple expansion and no major recovery credit. If Q3 organic growth confirms the Q2 rebound and Stryker keeps operating margins near 25%, the stock has room to re-rate toward the $375-$380 area implied by analyst targets. If the cyber/recovery narrative stumbles, the low forward multiple provides only modest valuation cushion.

As of 2026-08-27, RSI is 42.81 - soft but not oversold - and price sits 3.96% below the 20-day SMA, 1.81% below the 50-day SMA, and 5.23% below the 200-day SMA, with the 52-week range 281-396.86. The path of least resistance is still down/range-bound; a sustained move back above the 50-day would improve the near-term entry signal.

• Aging demographics and solid elective procedure volumes continue to support MedSurg, Orthopaedics, and Neurotechnology demand.
• Pricing and reimbursement pressure from private and government payers remains a structural margin headwind across MedTech.
• Import tariff relief and supply-chain stabilization helped Q2 2026 gross margin; policy shifts could reverse that tailwind.
• The late-Q1 Windows-based cybersecurity incident highlights IT/operational disruption risk in connected hospital environments.
• Regulatory scrutiny (FDA, EU MDR) and M&A integration demands create ongoing execution costs.

• Q3 2026 earnings (late October 2026): organic growth confirmation is the single biggest near-term catalyst.
• AVS intravascular lithotripsy integration and continued Mako robotics adoption could reinforce the growth premium.
• Further margin/FCF upside if tariffs stay low and hospital demand remains resilient.

• Adjusted EPS of $15.02 assumes a strong H2; any organic-growth slowdown would compress the multiple from a still-premium level.
• Recurrence of cyber/IT disruptions or supply-chain failures could recreate the Q1 2026 scenario.
• Regulatory, reimbursement, or tariff policy shifts could pressure the 25% operating-margin trajectory.
• Insider selling by senior leadership/directors during the summer is a caution flag, though not thesis-breaking by itself.

Stryker is a high-quality, defensive compounder with durable growth, expanding margins, and strong FCF; at 21.4x forward earnings it is not egregiously priced, but the soft technicals and Q1 event noise argue for patience and scaling in rather than aggressive chasing. As of this analysis, the risk/reward is balanced - a good business at a fair price, not a deeply mispriced one.

Calculated by applying a 25x justified forward P/E to consensus forward EPS of $15.02 (25 x $15.02 = $375.55). The 25x multiple reflects Stryker's ~20% expected EPS growth (PEG ~1.2), its defensive healthcare franchise, and a conservative discount to the premium multiples it has historically carried.